Cyclica

Cyclica

400-326 Adelaide St. W.
Toronto, Ontario M5V1R3
Phone: 800-379-6445
About the Company

Cyclica is a pioneer in the development of innovative, next generation in silico drug discovery and testing technologies that leverage integrated biological data to improve pharma R&D productivity. The company is commercializing the Ligand Explorer to addresses the rising cost of R&D in drug discovery and low regulatory approval rates of pre-market pharmaceutical and biophar-maceutical products that result in massive sunk R&D costs. Cyclica’s powerful Ligand Explorer platform reduces the failure risk of drug discovery projects by allowing clients to anticipate a drug candidate’s side effects prior to clinical trials, thereby enabling more informed R&D investment decisions. Furthermore, the technology allows researchers to overcome expensive project hurdles with data-guided Intelligent Molecular Redesign.

Technology

The Ligand Explorer is comprised of a novel drug testing approach that uses pre-computed, multi-scale structural proteomics databases that are biologically representative of conditions in the human body at 37 degrees Celsius. The platform uses these specialty databases with a chemical systems biology infrastructure to reliably identify problematic “off-target” protein-drug interactions that result in side effects and toxicity and are a major cause of attrition in discovery pipelines. Ligand Explorer is designed to be fast, accurate and also produce valuable data medicinal chemists can use for an iterative and informed optimization process we call Intelligent Molecular Redesign.